Drugs / NTQ1062
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06172322 | Dec 2023 → Apr 2025 | hormone receptor-positive breast cancer | Nanjing Chia-tai Tianqing Pharmaceutical | Unknown | No outcome recorded |
| Phase 1 | NCT06172309 | Sep 2021 → Apr 2024 | cancer | Nanjing Chia-tai Tianqing Pharmaceutical | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07393321 | Feb 2026 → Aug 2028 expected | Her2-receptor negative breast cancer | Nanjing Chia-tai Tianqing Pharmaceutical | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NTQ1062 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06172322 ↗ |
| Action | Inhibit | “small-molecule AKT inhibitor NTQ1062” NCT07393321 ↗ |
| Modality | Small molecule | “small-molecule AKT inhibitor NTQ1062” NCT07393321 ↗ |
| Route | Oral | “administered orally QD” NCT06172309 ↗ |